Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120

Nature Structural and Molecular Biology

Volumn 20, Issue 7, 2013, Pages 796-803

  Kong, Leopold ^a   Lee, Jeong Hyun ^a   Doores, Katie J ^a,b   Murin, Charles D ^a   Julien, Jean Philippe ^a   McBride, Ryan ^a   Liu, Yan ^c   Marozsan, Andre ^d   Cupo, Albert ^d   Klasse, Per Johan ^d   Hoffenberg, Simon ^e   Caulfield, Michael ^e   King, C Richter ^e   Hua, Yuanzi ^a   Le, Khoa M ^a   Khayat, Reza ^a   Deller, Marc C ^a   Clayton, Thomas ^a   Tien, Henry ^a   Feizi, Ten ^c   Sanders, Rogier W ^d,f   Paulson, James C ^a   Moore, John P ^d   Stanfield, Robyn L ^a   Burton, Dennis R ^a,b   Ward, Andrew B ^a   Wilson, Ian A ^a   more..

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^f ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; EPITOPE; GLYCAN; GLYCOPROTEIN GP 120; GLYCOSYLATED PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; NEUTRALIZING ANTIBODY;

ANIMAL CELL; ARTICLE; BINDING SITE; CONTROLLED STUDY; CRYSTAL STRUCTURE; CRYSTALLIZATION; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOTHERMAL TITRATION CALORIMETRY; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN INTERACTION; PROTEIN STRUCTURE; SURFACE PROPERTY; VIRUS NEUTRALIZATION;

1-DEOXYNOJIRIMYCIN; ALKALOIDS; AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ANTIBODIES, NEUTRALIZING; ANTIGEN-ANTIBODY REACTIONS; ANTIGENS, CD4; BINDING SITES, ANTIBODY; BIOPOLYMERS; CARBOHYDRATE SEQUENCE; CRYSTALLOGRAPHY, X-RAY; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; EPITOPES; GLYCOSYLATION; HEK293 CELLS; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MICROSCOPY, ELECTRON; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; MOLECULAR SEQUENCE DATA; POLYSACCHARIDES; PROTEIN CONFORMATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; STRUCTURE-ACTIVITY RELATIONSHIP;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84880161438     PISSN: 15459993     EISSN: 15459985     Source Type: Journal    
DOI: 10.1038/nsmb.2594     Document Type: Article

References (46)

1. Weiss, R.A. et al. Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients. Nature 316, 69-72 (1985).
2. Wei, X. et al. Antibody neutralization and escape by HIV-1. Nature 422, 307-312 (2003).
3. Zhang, M. et al. Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin. Glycobiology 14, 1229-1246 (2004).
4. Richman, D.D., Wrin, T., Little, S.J. & Petropoulos, C.J. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. USA 100, 4144-4149 (2003).
5. Scheid, J.F. et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333, 1633-1637 (2011).
6. Stamatatos, L., Morris, L., Burton, D.R. & Mascola, J.R. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine Nat. Med. 15, 866-870 (2009).
7. Walker, L.M. et al. Rapid development of glycan-specific, broad, and potent anti-HIV-1 gp120 neutralizing antibodies in an R5 SIV/HIV chimeric virus infected macaque. Proc. Natl. Acad. Sci. USA 108, 20125-20129 (2011).
8. Gray, E.S. et al. The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J. Virol. 85, 4828-4840 (2011).
9. Moore, P.L. et al. Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat. Med. 18, 1688-1692 (2012).
10. Burton, D.R. et al. A blueprint for HIV vaccine discovery. Cell Host Microbe 12, 396-407 (2012).
11. Mouquet, H. et al. Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc. Natl. Acad. Sci. USA 109, E3268-E3277 (2012).
12. Calarese, D.A. et al. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 300, 2065-2071 (2003).
13. Pejchal, R. et al. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 334, 1097-1103 (2011).
14. McLellan, J.S. et al. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480, 336-343 (2011).
15. Walker, L.M. et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326, 285-289 (2009).
16. Walker, L.M. et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477, 466-470 (2011).
17. Zhu, J. et al. Somatic populations of PGT135-137 HIV-1-neutralizing antibodies identified by 454 pyrosequencing and bioinformatics. Front. Microbiol. 3, 315 (2012).
18. Kwong, P.D. et al. Probability analysis of variational crystallization and its application to gp120, the exterior envelope glycoprotein of type 1 human immunodeficiency virus (HIV-1). J. Biol. Chem. 274, 4115-4123 (1999).
19. Tong, T., Crooks, E.T., Osawa, K. & Binley, J.M. HIV-1 virus-like particles bearing pure env trimers expose neutralizing epitopes but occlude nonneutralizing epitopes. J. Virol. 86, 3574-3587 (2012).
20. Zhou, T. et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445, 732-737 (2007).
21. Yang, X., Lipchina, I., Cocklin, S., Chaiken, I. & Sodroski, J. Antibody binding is a dominant determinant of the efficiency of human immunodeficiency virus type 1 neutralization. J. Virol. 80, 11404-11408 (2006).
22. Burton, D.R., Saphire, E.O. & Parren, P.W. A model for neutralization of viruses based on antibody coating of the virion surface. Curr. Top. Microbiol. Immunol. 260, 109-143 (2001).
23. Zemlin, M. et al. Expressed murine and human CDR-H3 intervals of equal length exhibit distinct repertoires that differ in their amino acid composition and predicted range of structures. J. Mol. Biol. 334, 733-749 (2003).
24. Kasturi, L., Chen, H. & Shakin-Eshleman, S.H. Regulation of N-linked core glycosylation: use of a site-directed mutagenesis approach to identify Asn-Xaa-Ser/Thr sequons that are poor oligosaccharide acceptors. Biochem. J. 323, 415-419 (1997).
25. Rudd, P.M. & Dwek, R.A. Glycosylation: heterogeneity and the 3D structure of proteins. Crit. Rev. Biochem. Mol. Biol. 32, 1-100 (1997).
26. Binley, J.M. et al. Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization. J. Virol. 84, 5637-5655 (2010).
27. Sanders, R.W. et al. The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J. Virol. 76, 7293-7305 (2002).
28. Fischer, P.B. et al. The -glucosidase inhibitor N-butyldeoxynojirimycin inhibits human immunodeficiency virus entry at the level of post-CD4 binding. J. Virol. 69, 5791-5797 (1995).
29. Julien, J.P. et al. Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. Proc. Natl. Acad. Sci. USA 110, 4351-4356 (2013).
30. Liu, J., Bartesaghi, A., Borgnia, M.J., Sapiro, G. & Subramaniam, S. Molecular architecture of native HIV-1 gp120 trimers. Nature 455, 109-113 (2008).
31. Chen, L. et al. Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science 326, 1123-1127 (2009).
32. Weis, W.I. & Drickamer, K. Structural basis of lectin-carbohydrate recognition. Annu. Rev. Biochem. 65, 441-473 (1996).
33. Azoitei, M.L. et al. Computation-guided backbone grafting of a discontinuous motif onto a protein scaffold. Science 334, 373-376 (2011).
34. Guenaga, J. et al. Heterologous epitope-scaffold prime:boosting immuno-focuses B cell responses to the HIV-1 gp41 2F5 neutralization determinant. PLoS ONE 6, e16074 (2011).
35. Sanders, R.W. et al. Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type J. Virol. 76, 8875-8889 (2002).
36. Hoffenberg, S. et al. Identification of an HIV-1 Clade A envelope that exhibits broad antigenicity and neutralization sensitivity and elicts antibodies targeting three distinct epitopes. J. Virol. 87, 5372-5283 (2013).
37. Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307-326 (1997).
38. Adams, P.D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213-221 (2010).
39. Li, M. et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79, 10108-10125 (2005).
40. Dunlop, D.C. et al. Polysaccharide mimicry of the epitope of the broadly neutralizing anti-HIV antibody, 2G12, induces enhanced antibody responses to self oligomannose glycans. Glycobiology 20, 812-823 (2010).
41. Lander, G.C. et al. Appion: an integrated, database-driven pipeline to facilitate EM image processing. J. Struct. Biol. 166, 95-102 (2009).
42. Voss, N.R., Yoshioka, C.K., Radermacher, M., Potter, C.S. & Carragher, B. DoG Picker and TiltPicker: software tools to facilitate particle selection in single particle electron microscopy. J. Struct. Biol. 166, 205-213 (2009).
43. Sorzano, C.O. et al. A clustering approach to multireference alignment of single-particle projections in electron microscopy. J. Struct. Biol. 171, 197-206 (2010).
44. van Heel, M., Harauz, G., Orlova, E.V., Schmidt, R. & Schatz, M. A new generation of the IMAGIC image processing system. J. Struct. Biol. 116, 17-24 (1996).
45. Ludtke, S.J., Baldwin, P.R. & Chiu, W. EMAN: semiautomated software for high-resolution single-particle reconstructions. J. Struct. Biol. 128, 82-97 (1999).
46. Hohn, M. et al. SPARX, a new environment for Cryo-EM image processing. J. Struct. Biol. 157, 47-55 (2007).